SEC Tracker
Get the app

Trevi Therapeutics TRVI

Trevi Therapeutics reports Q3 2026 financial results

Trevi Therapeutics (TRVI) filed an 8-K with the SEC on Nov 9, 2026, 4:27 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities: $299.4 million as of September 30, 2026
  2. R&D expenses increased to $19.1 million in Q3 2026 from $10.1 million in Q3 2025
  3. Phase 3 OCEAN-2 trial for IPF-related chronic cough initiated in Q3 2026
  4. FDA meeting on non-IPF ILD-related chronic cough program held in October 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Trevi Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.